Scotia Launches Dyslexia Supplement

27 November 1995

Scotia has launched a dietary supplement called Efalex in the UK, which may help ameliorate some of the symptoms of the learning disorder dyslexia. The product contains gammalinolenic acid, docosahexaenoic acid and arachidonic acid, plus thyme oil antioxidants.

The rationale behind the product comes from work conducted by Jacqueline Stordy of the University of Surrey, which suggested that dietary supplementation of these lipids could resolve night blindness in dyslexics (Marketletter October 2). Dr Stordy hopes that this approach may also resolve other symptoms of the disorder.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight